



Fortis Healthcare Limited
Support Office:
Tower A, Unitech Business Park,
Block - F, South City 1, Sector - 41,
Gurgaon, Haryana - 122001 (India)
Tel : 0124 492 1021
Fax : 0124 492 1041
Ambulance : 105010
E-mail : secretarial@fortishealthcare.com
Website : www.fortishealthcare.com

FHL/SEC/STEX/RR/2015-16

May 26, 2016

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai - 400051
Scrip Symbol: FORTIS

BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001
Scrip Code: 532843

Sub: Outcome of the Board Meeting

Dear Sirs,

This is to inform you that the Board of Directors of the Company at its meeting held today, *inter-alia*, considered and approved the Audited Consolidated and Standalone Financial Results of the Company for the quarter and year ended on March 31, 2016.

Further, the Board has also decided to assess and evaluate a demerger of the diagnostics business of the Company in addition to other options that may be available to unlock and monetize value inherent in this business. The same is subject to finalization by the Board and other stakeholders.

A press release to be issued with respect to above is also enclosed herewith for your reference along with the copy of aforesaid audited financial results.

The meeting commenced at 9.30 am and concluded at 2.45 p.m.

Thanking you,

Yours faithfully,

For Fortis Healthcare Limited


Rahul Rahjan
Company Secretary
Membership No.: A17035

FORTIS HEALTHCARE LIMITED


Regd. Office: Escorts Heart Institute and Research Centre, Okhla Road, New Delhi - 110 025 (India)
Tel: +91-11-2682 5000, Fax: +91-11-4162 8435, CIN: L85110DL1996PLC076704

FORTIS HEALTHCARE LIMITED

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

(₹ in lacs)

Particulars	Consolidated				Standalone			
	Quarter ended		Year ended		Quarter ended		Year ended	
	31-Mar-16 (Audited) (Refer note 2)	31-Dec-15 (Unaudited)	31-Mar-15 (Audited) (Refer note 2)	31-Mar-16 (Audited) (Refer note 2)	31-Mar-15 (Audited) (Refer note 2)	31-Mar-16 (Audited)	31-Mar-15 (Audited)	31-Mar-16 (Audited)
1. Income from operations	106,132	102,751	421,215	408,863	15,052	14,672	59,667	59,578
2. Other operating income	2,697	1,361	6,360	5,150	351	378	1,492	1,486
3. Total income from operations	108,829	104,112	427,575	414,013	15,403	15,050	61,159	61,064
4. Expenses								
(a) Cost of material consumed	24,468	23,331	95,821	94,933	3,626	3,407	14,455	14,730
(b) Employee benefits expenses	22,083	20,039	83,577	84,207	4,688	4,332	17,687	18,245
(c) Hospital service fee	14,866	14,786	59,199	56,396	3,325	3,302	13,247	12,808
(d) Professional charges to doctors	12,753	12,559	48,321	42,556	1,798	2,110	7,802	7,396
(e) Other expenses	31,035	28,329	118,723	122,554	4,242	4,574	19,754	22,953
Total	105,228	99,524	405,641	400,635	17,679	17,725	72,945	75,932
5. Earnings before other income, depreciation and amortisation, finance costs, exceptional items (3-4)	3,601	4,588	21,934	13,378	(2,276)	(2,675)	(11,786)	(14,868)
6. Other income	4,543	1,267	14,702	9,874	3,887	3,294	14,724	21,791
7. Earnings before depreciation and amortisation, finance costs, exceptional items (5+6) (EBITDA)	8,144	5,855	36,636	23,252	1,611	619	2,938	6,923
8. Net depreciation/impairment & amortisation expenses	7,136	5,488	23,652	26,279	826	569	2,542	2,713
9. Profit/(Loss) from operations before finance costs, exceptional items (7-8)	1,006	367	13,584	(3,027)	785	50	396	4,210
10. Finance costs	3,663	2,395	12,495	15,354	2,185	1,452	6,214	8,063
11. Profit/(Loss) from operations before exceptional items (9-10)	(2,657)	(2,028)	1,089	(18,361)	(1,400)	(1,402)	(5,818)	(3,853)
12. Exceptional gain/(loss) (refer note 7)	(5,422)	(5,211)	(3,319)	33	-	(276)	(1,533)	265
13. Profit/(Loss) from operations before tax (11+12) (including profit/loss) attributable to discontinued operations, refer note 2)	(9,079)	(5,739)	(2,230)	(18,328)	(1,400)	(1,678)	(7,351)	(3,588)
14. Tax expense/(credit)	1,180	1,030	4,583	626	-	-	-	(197)
15. Profit/(Loss) from ordinary activities after tax (13-14)	(10,259)	(6,769)	(5,913)	(18,954)	(1,400)	(1,678)	(7,351)	(3,391)
16. Less: Minority interest in profit/loss	533	244	2,130	1,374	-	-	-	-
17. Add: Share in profit of associate companies	1,706	1,436	6,558	5,958	-	-	-	-
18. Net profit/(Loss) after taxes, minority interest and share of profit of associates (15-16+17)	(9,056)	(5,525)	(2,485)	(14,370)	(1,400)	(1,678)	(7,351)	(3,391)
19. Paid-up equity share capital (Face Value ₹10 per Share)	48,313	46,312	46,313	46,281	46,313	46,312	46,313	46,281
20. Reserves excluding revaluation reserves ₹10 per Share)			553,416	358,482			314,514	321,671
21. Earnings per share								
- Basic	(1.96)	(1.19)	(0.38)	(3.10)	(0.30)	(0.36)	(0.16)	(0.73)
- Diluted	(2.06)	(1.25)	(0.44)	(3.31)	(0.30)	(0.36)	(0.16)	(0.73)



FORTIS HEALTHCARE LIMITED

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

Notes to the results

1. The above financial results for the quarter and year ended March 31, 2016 have been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their respective meetings held on May 25, 2016 and May 26, 2016.
2. The figures for the quarter ended March 31, 2016 and March 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2016 and March 31, 2015 respectively and the unaudited published year to date figures up to December 31, 2015 and December 31, 2014 respectively, being the end of the third quarter of the respective financial years, which were subjected to a limited review.

3. Segment Reporting

Business segments:

The Group is primarily engaged in the business of healthcare services, which in the opinion of management is considered to be the only reportable business segment as per Accounting Standard 17 on 'Segment Reporting' issued by The Institute of Chartered Accountants of India as notified under section 133 of the Companies Act, 2013. Healthcare services include various patient care services delivered through clinical establishment, medical services companies, pathology and radiology services etc.

Geographical segments:

The Group operates in the business segment explained above in two principal geographical areas, India and outside India. The geographical segments have been identified as secondary segment. The Group operates in 2 main geographical segments, which contributes more than 10% of the Groups' revenue or segment assets. Outside India, Group now primarily operates in Dubai and Mauritius.

Revenue from operations – by geographical segments

The following table shows the distribution of the Groups' consolidated revenues by geographical segment:
(₹ in lacs)

Region	Quarter ended		Year ended	
	March 31, 2016	December 31, 2015	March 31, 2016	March 31, 2015
India	106,967	102,940	421,332	392,968
Outside India*	1,862	1,172	6,243	21,045
Total	108,829	104,112	427,575	414,013

* Includes revenue relating to discontinued operations (see note 8 below).



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

Carrying value of Assets and additions to tangible and intangible fixed assets- by location of assets

The following table shows the carrying amount of segment assets and additions to tangible and intangible fixed assets by geographical area in which the assets are located.

Region	Carrying amount of Segment assets		Additions to Fixed & Intangible assets	
	March 31, 2016	March 31, 2015	March 31, 2016	March 31, 2015
India	586,194	552,032	41,249	40,290
Outside India	136,929	209,525	67	1,435
Total	723,123	761,557	41,316	41,725

(₹ in lacs)

4. Other income includes interest income, foreign exchange fluctuation gain (net), profit on sale of assets (net), profit on sale (net)/ dividend on investments, forward cover premium amortization (net) and miscellaneous income, etc. whichever is relevant for the period.
5. In case of one of the subsidiary ("Escorts Heart Institute and Research Centre Limited") ("EHIRCL"), that was formed after amalgamation of Escorts Heart Institute and Research Centre ("EHIRC"), Delhi Society with EHIRC, Chandigarh Society and thereafter registration of EHIRC, Chandigarh Society as a company.

a) Delhi Development Authority ("DDA") had terminated the lease deeds and allotment letters relating to land parcels on which hospital of EHIRCL exists. Consequent to termination, DDA issued show cause notice and initiated eviction proceedings against EHIRCL. Both these matters are currently pending in various courts of law. Based on the experts' opinions, management is confident that EHIRCL will be able to suitably defend the termination order and eviction proceedings and accordingly considers that no adjustments are required to the financial result.

b) Further, EHIRCL also has open tax demands of ₹ 7,315 lacs (after adjusting ₹ 3,658 lacs for which the Company has a legal right to claim from erstwhile promoters and ₹ 11,996 lacs of an escrow account which was maintained out of sale consideration payable by the Company to the erstwhile promoters) for various assessment years. During the previous year, the Commissioner of Income Tax (Appeals) decided the case in favour of EHIRCL. Income Tax Department has filed an appeal before ITAT, which is yet to be fixed for hearing.


c) In relation to the order of the Honorable High Court of Delhi relating to provision of free treatment/ beds to poor, Directorate of Health Services ("DHS"), Government of NCT of Delhi, DHS appointed firm to calculate "unwarranted profits" arising to it due to non-compliance. During the year 2013-14, the Special Committee of DHS stated that before giving a formal hearing to the hospital, a formal intimation shall be given regarding the recoverable amount as per calculation of the appointed firm, which as per their method of calculations amounts to ₹ 73,266 lacs for the period 1984-85 to 2011-12, seeking hospital's comments and inputs, if any. The company responded to such intimation explaining errors and objections to the calculations. During the previous quarter, EHIRCL has received notice from DHS to appear for a formal and final hearing raising demand of recoverable amount to ₹ 50,336 lacs for the period till FY 2006 -2007 in terms of above referred judgement. On receipt of hearing notice, during the current quarter, the Company has responded to such notice explaining errors and objections to the calculations. Based on its internal assessment and advice from its counsels on the basis of the documents available, management believes that it is in compliance of conditions of free treatment and free beds to the poor and does not anticipate any liability after proper hearing with DHS.



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

6. Statement of Assets and Liabilities :

Particulars		Consolidated		Standalone	
		As at March 31, 2016	As at March 31, 2015	As at March 31, 2016	As at March 31, 2015
(₹ in lacs)					
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share capital	46,313	46,281	46,313	46,281
	(b) Reserves and surplus	353,416	358,482	314,514	321,671
		399,729	404,763	360,827	367,952
	Sub-total - Shareholders' funds				
2	Minority interest	14,310	15,294	-	-
3	Compulsorily convertible preference shares issued by subsidiary companies outside the Group	67,000	67,000	-	-
4	Non-current liabilities				
	(a) Long-term borrowings	84,115	100,440	61,572	59,753
	(b) Deferred tax liabilities (net)	35	2,388	-	-
	(c) Other long-term liabilities	5,922	6,760	2,393	2,336
	(d) Long-term provisions	4,500	4,687	1,267	1,141
		94,572	114,275	65,232	63,230
	Sub-total - Non-current liabilities				
5	Current liabilities				
	(a) Short-term borrowings	52,191	2,699	42,882	-
	(b) Trade payables	57,216	52,508	14,884	9,693
	(c) Other current liabilities	32,546	98,759	5,375	73,844
	(d) Short-term provisions	5,559	6,259	1,237	1,222
		147,512	160,225	64,378	84,759
	Sub-total - Current liabilities				
		723,123	761,557	490,937	515,921
	TOTAL - EQUITY AND LIABILITIES				
B	ASSETS				
1	Non-current assets				
	(a) Fixed assets	178,314	206,551	31,530	32,619
	(b) Goodwill on consolidation (net)	170,859	188,933	-	-
	(c) Goodwill on acquisition	48,483	49,092	3,293	3,293
	(d) Non-current investments	107,843	84,768	241,550	210,273
	(e) Deferred tax assets (net)	5,095	3,099	-	-
	(f) Long-term loans and advances	65,189	58,605	90,538	64,091
	(g) Other non-current assets	3,276	3,587	3,594	6,655
		579,059	594,645	370,805	316,931
	Sub-total - Non-current assets				



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

(₹ in lacs)


	Particulars	Consolidated		Standalone	
		As at March 31, 2016	As at March 31, 2015	As at March 31, 2016	As at March 31, 2015
2	Current assets				
	(a) Current investments	56,391	61,582	22,000	30,840
	(b) Inventories	6,190	6,397	583	724
	(c) Trade receivables	44,378	40,937	10,259	9,351
	(d) Cash and bank balances	17,739	18,965	925	629
	(e) Short-term loans and advances	11,250	30,165	71,195	136,006
	(f) Other current assets	7,915	8,866	15,170	21,240
	Sub-total - Current assets	144,064	166,912	120,132	198,990
	TOTAL - ASSETS	723,123	761,557	490,937	515,921

7. Exceptional gain/ (loss) included in the above consolidated financial results include:

(₹ in lacs)

Particulars	Quarter ended		Year ended	
	March 31, 2016	December 31, 2015	March 31, 2016	March 31, 2015
a) Loss on impairment of investment and assets held in subsidiary companies	(6,263)	-	(6,263)	-
b) Loss on closure/ disposal of certain operations by the group	(222)	(1,566)	(4,155)	(158)
c) Statutory Bonus (see note below)	63	(1,645)	(1,582)	-
d) Gain/(Loss) on sale of investment in Radlink Asia Pte Limited ("Radlink") [Refer note 8 (a)]	-	-	7,800	-
e) Gain on sale of investment in Fortis Healthcare Singapore Pte Limited ("FHS") [Refer note 8 (b)]	-	-	881	-
f) Gain on sale of net assets related to Mohali clinical establishment to Escorts Heart and Super Speciality Hospital Limited, one of the subsidiary of RHT	-	-	-	191
Net exceptional gain/ (loss)	(6,422)	(3,211)	(3,319)	33

Note : Statutory bonus recorded as an exceptional item represents the amounts accrued/ reversed towards incremental bonus payable to existing and deemed employees by the Group for the period from April 1, 2014 to December 31, 2015 due to enactment of The Payment of Bonus (Amendment) Act, 2015 with retrospective effect from April 1, 2014.



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

8. a) Discontinued operations relating to Radlink-Asia Pte Limited, Singapore ("Radlink")

During the previous year, Fortis Healthcare International Pte Limited (FHIPL), a wholly owned subsidiary of the Company announced its decision to divest its 100% shareholding in Radlink.

The transaction was completed on May 12, 2015 post approvals by the shareholders of Radlink and other regulatory authorities. The investment was sold to Fullerton Healthcare Group Pte. Limited for a consideration of SGD 111 million. Accordingly, assets and liabilities of Radlink do not form part of the consolidated assets and liabilities of the Company w.e.f. May 12, 2015. Such deconsolidation resulted in a net gain of ₹ 7,800 lacs and is included as an exceptional item in the year ended March 31, 2016.

The revenue and expenses in respect of the activities attributable to above discontinued operations included in the consolidated financial results are as follows:



(₹ In lacs)

Particulars	Quarter ended		Year ended	
	March 31, 2016	December 31, 2015	March 31, 2016	March 31, 2015
Total income	-	-	1,062	13,546
Total expenses	-	-	934	11,449
Profit before tax	-	-	128	2,097
Tax expenses	-	-	27	172
Profit after tax	-	-	101	1,925

The carrying amounts in relation to Radlink is as follow:-

(₹ In lacs)

Particulars	March 31, 2016	March 31, 2015
Total assets	-	14,419
Total liabilities	-	3,751
Net Assets	-	10,668



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

b) Discontinued operations relating to Fortis Healthcare Singapore Pte Limited ('FHS')

During the previous year, Fortis Healthcare International Pte Limited (FHPL), a wholly owned subsidiary of the Company announced its decision to divest 100% shareholding in FHS which holds and operates Fortis Surgical Hospital to Concord Medical Services (International) Pte Limited for SGD 55 million.

The transaction was concluded on April 7, 2015. Accordingly, assets and liabilities of FHS do not form part of the consolidated assets and liabilities of the Company w.e.f. April 7, 2015. Such deconsolidation resulted in a net gain of ₹ 881 lacs and is included as an exceptional item in the year ended March 31, 2016.

The revenue and expenses in respect of the activities attributable to above discontinued operations included in the consolidated financial results are as follows:

Particulars	Quarter ended		Year ended	
	March 31, 2016	December 31, 2015	March 31, 2016	March 31, 2015
Total income	-	-	-	4,072
Total expenses	-	-	-	13,303
Loss before tax	-	-	-	(9,231)
Tax expenses	-	-	-	-
Loss after tax	-	-	(2,282)	(9,231)

(₹ In lacs)

The carrying amounts in relation to FHS is as follow:-

Particulars	March 31, 2016	March 31, 2015
Total assets	-	59,808
Total liabilities	-	86,331
Net Assets/(liabilities)	-	(26,523)

(₹ In lacs)

9. During the quarter ended June 30, 2015, as per the agreed issue terms, the Company redeemed on due date the outstanding USD 100 million 5% Foreign Currency Convertible Bonds (FCCBs) listed on the Luxembourg stock exchange.

10. As permitted by the Companies Act, the Group has elected to present earnings before interest, tax, depreciation and amortization (EBITDA) as a separate line item on the face of the statement of profit and loss. The same classification is also followed while presenting the financial results required pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In its measurement, the Group includes other income, but does not include depreciation and amortization expense, finance costs and tax expense.



FORTIS HEALTHCARE LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS

11. The previous quarters/ periods/ years' figures have been regrouped/ reclassified wherever necessary to correspond with the current quarters/ periods' classification/ disclosure.

Date: May 26, 2016
Place: Gurgaon

For and on behalf of the Board of Directors


Malvinder Mohan Singh
Executive Chairman



**INDEPENDENT AUDITOR'S REPORT
TO THE BOARD OF DIRECTORS OF
FORTIS HEALTHCARE LIMITED**

1. We have audited the accompanying Standalone Financial Results ("Results") of **FORTIS HEALTHCARE LIMITED** ("the Company") for the year ended 31 March, 2016 included in the accompanying Statement of Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Results included in the Statement, which are the responsibility of the Company's Management and approved by the Board of Directors, have been prepared on the basis of the related financial statements which is in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Results included in the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Results included in the Statement are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Results included in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Results included in the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Results included in the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Results included in the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. In our opinion and to the best of our information and according to the explanations given to us, Results included in the Statement:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
 - ii. give a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India, of the net loss and other financial information of the Company for the year ended 31 March 2016.

W,

Deloitte
Haskins & Sells LLP

4. The Statement includes the results for the Quarter ended 31 March, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)





V. Srikumar
Partner

(Membership No. 084494)

Mumbai
26 May, 2016

FORTIS HEALTHCARE LIMITED
FORM A (for audit report with unmodified opinion)

1	Name of the Company	Fortis Healthcare Limited
2	Annual standalone financial statements for the year ended	March 31, 2016
3	Type of Audit observation	Unqualified
4	Frequency of observation	Not applicable
5	To be signed by- - Chief Executive Officer - Chief Financial Officer - Chairman- Audit and Risk Management Committee DIN : 00101235 Place : Gurgaon Date : 26 May, 2016 Refer to our Auditors' report dated 26 May, 2016 on the standalone financial statements of the Company For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No. 117366W/W-100018)  V. Srikumar Partner (Membership No. 084494) Place : Mumbai Date : 26 May, 2016	 BHAVDEEP SINGH  GAGANDEEP SINGH BEDI  DR. BRIAN WILLIAM TEMPEST

Deloitte Haskins & Sells LLP

Chartered Accountants
Indiabulls Finance Centre
Tower 3, 27th - 32nd Floor
Senapati Bapat Marg
Elphinstone Road (West)
Mumbai - 400 013
Maharashtra, India

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF FORTIS HEALTHCARE LIMITED

Tel: +91 (022) 6185 4000
Fax: +91 (022) 6185 4501/4601

1. We have audited the Consolidated Financial Results ("Consolidated Results") of **FORTIS HEALTHCARE LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its jointly controlled entities and its share of the profit of its associates for the year ended 31 March, 2016 included in the accompanying Statement of Standalone and Consolidated Financial Results ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Consolidated Results included in the Statement, which are the responsibility of the Holding Company's Management and approved by the Board of Directors, have been prepared on the basis of the related consolidated financial statements which is in accordance with the Accounting Standards, prescribed under Section 133 of the Companies Act, 2013, as applicable, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Consolidated Results included in the Statement.
2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Consolidated Results included in the Statement are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Consolidated Results included in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Consolidated Results included in the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Holding Company's preparation and fair presentation of the Consolidated Results included in the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Consolidated Results included in the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. We did not audit the financial statements of 3 subsidiaries and 1 jointly controlled entities included in the Consolidated Results included in the Statement, whose financial statements reflect the Group's share of total assets of Rs. 11,783 lacs as at 31 March, 2016, the Group's share of total revenues of Rs. 4,779 lacs for the year ended 31 March, 2016, and the Group's share of total profit after tax of Rs. 434 lacs for the year ended 31 March 2016, as considered in the Consolidated Results included in the Statement. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the Consolidated Results in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and jointly controlled entities, is based solely on the reports of the other auditors.

We also did not audit the financial statements of 1 overseas joint venture included in the Consolidated Results included in the Statement, whose financial statements, prepared under Nepal Accounting Standard "NAS", reflect the Group's share of total assets of Rs. 180 lacs as at 31 March, 2016, the Group's share of total revenues of Rs. 228 lacs for the year ended 31 March, 2016, and the Group's share of total profit after tax of Rs. 9 lacs for the year ended 31 March 2016, as considered in the Consolidated Results in the Statement. Further, we did not audit

W.

the financial statements of 3 overseas associates included in the Consolidated Results included in the Statement, whose financial statements, prepared under International Financial Reporting Standards "IFRS", reflect the Group's share of net loss of Rs. 4,478 lacs, for the year ended 31 March, 2016, as considered in the Consolidated Results included in the Statement. The financial statements of the joint venture and associates have been prepared in accordance with NAS and IFRS respectively and have been audited by other auditors who have submitted their conclusions, prepared under generally accepted auditing standards of their respective countries. The Management of the Holding Company has converted these financial statements of the joint venture and associate to accounting principles generally accepted in India, for the purpose of the preparation of the Consolidated Results under accounting principles generally accepted in India. Our report on Consolidated Results included in the Statement, thus in so far it relates to amounts and disclosures included in respect of the joint venture and associates, is based solely on the reports of other auditors and our audit of the conversion process followed by the Management.

4. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors referred to in paragraph 3 above, the Consolidated Results included in the Statement:

a. includes the results of the following entities:

- I. Fortis Healthcare Limited
- II. Fortis Hospitals Limited ("FHsL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and associate:
 - i. Birdie & Birdie Realtors Private Limited (wholly owned subsidiary of FHsL)
 - ii. Fortis C-Doc Healthcare Limited (subsidiary of FHsL)
 - iii. Fortis Health Management (East) Limited (subsidiary of FHsL)
 - iv. Fortis Cancer Care Limited ("FCCL") (wholly owned subsidiary of FHsL) and the results of its subsidiary Lalitha Healthcare Private Limited
 - v. Fortis Cauvery (jointly controlled entity of FCCL)
 - vi. Fortis Malar Hospitals Limited (subsidiary of FHsL) and the results of its wholly owned subsidiary Malar Stars Medicare Limited.
 - vii. Fortis Emergency Services Limited (associate of FHsL)
 - viii. Stellant Capital Advisory Services Private Limited with effect from 03 November, 2015 (wholly owned subsidiary of FHsL) and the results of its wholly owned subsidiary Religare Health Trust Trustee Manager Pte Limited with effect from 01 February, 2016
- III. Escorts Heart Institute and Research Centre Limited ("EHIRCL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and associate:
 - i. Fortis Health Staff Limited (subsidiary of EHIRCL)
 - ii. Fortis Asia Healthcare Pte. Limited (wholly owned subsidiary of EHIRCL) and the results of its wholly owned subsidiary Fortis Healthcare International Pte. Limited ("FHIPL")
 - iii. Radlink Asia Pte. Limited (wholly owned subsidiary of FHIPL) and the results of its subsidiaries and associates up to 12 May, 2015
 - iv. Fortis Healthcare Singapore Pte. Limited (wholly owned subsidiary of FHIPL) up to 05 April, 2015
 - v. Lanka Hospitals Corporation Plc (associate of FHIPL)
 - vi. Fortis Healthcare Middle East LLC (subsidiary of FHIPL)
 - vii. Mena Healthcare Investment Company Limited (subsidiary of FHIPL) and the results of its wholly owned subsidiary Medical Management Company Limited
 - viii. SRL Diagnostics FZ-LLC (wholly owned subsidiary of FHIPL)

102

IV. SRL Limited ("SRL") (subsidiary of the Holding Company) and the results of its subsidiaries and associate:

- i. SRL Diagnostics Private Limited (wholly owned subsidiary of SRL)
- ii. SRL Reach Limited (wholly owned subsidiary of SRL)
- iii. DDRC SRL Diagnostics Services Private Limited (jointly controlled entity of SRL)
- iv. Super Religare Reference Laboratories (Nepal) Private Limited (jointly controlled entity of SRL)

V. Hiranandani Healthcare Private Limited (subsidiary of the Holding Company)

VI. Fortis Healthcare International Limited ("FHIL") (wholly owned subsidiary of the Holding Company) and results of its subsidiaries and associate:

- i. Fortis Global Healthcare (Mauritius) Limited (wholly owned subsidiary of FHIL)
- ii. Fortis Medicare International Limited (associate of FHIL)
- iii. Religare Health Trust and its subsidiaries (associates of FHIL)
- iv. Medical and Surgical Centre Limited (associate of FHIL)

VII. Fortis La Femme Limited (wholly owned subsidiary of the Holding Company)

- b. is presented in accordance with the requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
 - c. gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the consolidated net loss and other financial information of the Group for the year ended 31 March 2016.
5. The Statement includes the results for the Quarter ended 31 March 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
6. The Consolidated Results includes the unaudited financial statements of 6 subsidiaries and 1 jointly controlled entities, whose financial statements reflect the Group's share of total assets of Rs. 6,130 lacs as at 31 March 2016, the Group's share of total revenue of Rs. 6,372 lacs for the year ended 31 March 2016, and the Group's share of total profit after tax of Rs. 41 lacs for the year ended 31 March 2016, as considered in the Consolidated Results included in the Statement. The Consolidated Results also includes the Group's share of profit after tax of Rs. 1,254 lacs for the year ended 31 March 2016, as considered in the Consolidated Results included in the Statement, in respect of 4 associates, based on their unaudited financial statements. Our opinion on the Consolidated Results included in the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, jointly controlled entities and associates, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Management, these financial statements are not material to the Group.

Our opinion on the Consolidated Results included in the Statement, is not modified in respect of our reliance on the financial statements certified by the Management.

W,

Deloitte
Haskins & Sells LLP

7. We draw attention to notes 5 to the Statement, regarding matters relating to income tax demands, termination of certain land leases allotted by Delhi Development Authority (DDA), and non-compliance with order of the Honorable High court of Delhi in relation to provision of free treatment/beds to poor against one of the subsidiaries ("Escorts Heart Institute and Research Centre Limited"). Based on the advice given by external legal counsel, no provision/adjustment has been considered necessary by the Management in this regard in the Consolidated Results included in the Statement.

Our opinion on the Consolidated Results included in the Statement, is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



V. Srikumar
Partner
(Membership No. 084494)

Mumbai
26 May, 2016


FORTIS HEALTHCARE LIMITED
FORM A (for audit report with unmodified opinion)

1	Name of the Company	Fortis Healthcare Limited
2	Annual consolidated financial statements for the year ended	March 31, 2016
3	Type of Audit observation	<u>Unqualified – Emphasis of Matter</u> (A) Emphasis of matter relating to income tax demands and termination of certain land leases allotted by Delhi Development Authority (DDA), against one of the subsidiary ("Escorts Heart Institute and Research Centre Limited"). a) Whether appeared first time: No b) Whether repetitive: Yes c) Since how long period: Since financial year ending March 31, 2013, however qualification and subject to opinion for same matter was given from financial year ending March 31, 2007 till March 31, 2012.
4	Frequency of observation	(B) Emphasis of matter relating to non-compliance with order of the Honorable High court of Delhi in relation to provision of free treatment/beds to poor against one of the subsidiaries ("Escorts Heart Institute and Research Centre Limited"). a) Whether appeared first time: No b) Whether repetitive: Yes c) Since how long period: Since financial year ending March 31, 2014.
5	To be signed by-	 BHAVDEEP SINGH • Chief Executive Officer


Fortis Healthcare Limited – Form A on the Consolidated financial statements of the Company

10/

- Chief Financial Officer


GAGANDEEP SINGH BEDI


- Chairman- Audit and Risk Management Committee
DIN : 00101235


DR. BRIAN WILLIAM TEMPEST

Place : Gurgaon
Date : 26 May, 2016

Refer to our Auditors' report dated 26 May, 2016 on the consolidated financial statements of the Company

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



V. Srikumar
Partner
(Membership No. 084494)

Place : Mumbai
Date : 26 May, 2016



PRESS RELEASE

FORTIS RECORDS UPTICK IN CONSOLIDATED INDIA REVENUES AND MARGINS IN FY16

CONSOLIDATED REVENUE AT RS 4,213 CR VS RS 3,928 CR IN FY 15

MARGIN IMPROVES TO 16.4% in FY 16 VS 15.4% IN PRECEDING YR. OPERATING

EBITDAC AT RS 692 CR;

OPERATING EBITDA UP 46% AT RS 235 CR

Q4 FY16 CONSOLIDATED INDIA REVENUES UP AT RS 1070 CR VS RS 1016 CR IN Q4

FY15 OPERATING EBITDAC AT RS 174 CR; MARGIN OF 16.3%

NET DEBT TO EQUITY RATIO AT A HEALTHY 0.16x

BOARD TO EVALUATE VALUE UNLOCKING OPTIONS FOR SRL, INCLUDING DEMERGER

Gurgaon, May 26, 2016: Fortis Healthcare Ltd. (Fortis), India's leading healthcare delivery Company, today, announced its consolidated results for the quarter and year ended March 31, 2016 (Q4FY16 and FY16).

The Board of the Company has decided to assess and evaluate a demerger of the diagnostics business of the Company in addition to other options that may be available to unlock and monetize value inherent in this business. The same is subject to finalization by the Board and other stakeholders.

India Business - Key Financial Highlights for the year (FY16)

- Consolidated India Business Revenues at Rs 4,213 Cr, up 7.3%.
- Consolidated Operating EBITDAC for the India Business (EBITDA before net business trust costs) was at Rs 692 Cr, +14.2%, representing a margin of 16.4% versus 15.4% in the previous year.
- Consolidated Operating EBITDA for the India Business was at Rs 235 Cr, up 46%, representing a margin of 5.6% versus a margin of 4.1% in the previous year.
- PBT before exceptional and foreign exchange gain / (loss) witnessed significant improvement at Rs (30) Cr versus Rs (116.6) Cr in the previous year
- FY16 revenues for the India hospital business were at Rs 3,449 Cr, up 7.6% as compared to FY15. Operating EBITDAC was at Rs 508 Cr, a stable growth of 11%. The EBITDAC for the India hospital business represents a margin of 14.7%, up from 14.3% in FY15.

- Key operational parameters in the Company's hospital business continued to see a healthy uptrend. The ARPOB (Average Revenue per Occupied Bed) grew to Rs 1.37 Cr compared to Rs 1.26 Cr in FY15, an increase of 9%. ALOS (Average length of stay) was at 3.56 days versus 3.64 days showing that patients could be discharged earlier due to their faster recovery. In addition, Occupancy improved to 72% versus 70% in FY 15 respectively.
- The newly launched hospitals continued to witness good traction. FMRI, the Company's flagship facility recorded revenues of Rs 413 Cr in FY16, a healthy growth of 18% over the previous year. The flagship facility has become the highest ARPOB generating hospital in the Company's network of multi-specialty hospitals. In a short span of time following its launch in May 2013, the ARPOB at FMRI rose to Rs 2.51 Cr in FY16 (FY15: Rs 2.15 Cr). The hospital continues to record a strong improvement in operating profitability. Revenue at Fortis Ludhiana, the other new facility, continued to ramp up. It recorded a revenue of Rs 73 Cr, an increase of 32% over the corresponding previous period.
- The India diagnostics business recorded revenues (net of inter company elimination) of Rs 764 Cr, up 6%. The operating EBITDA was at Rs 184 Cr, up 25%, representing an EBITDA margin of 24.1% against 20.4% in FY15.

*EBITDAC refers to EBITDA before net business trust costs

India Business - Key Financial Highlights for the quarter (Q4FY16)

- Consolidated India Business Revenues were at Rs 1,070 Cr versus Rs 1,016 Cr in the corresponding previous quarter.
- Consolidated India Business Operating EBITDAC (EBITDA before net business trust costs) was at Rs 174 Cr, representing a 16.3% margin, comparable to the 16.5% in the corresponding previous quarter and better than the 15.7% margin in the trailing quarter.
- Consolidated India Business EBITDA at Rs 61 Cr, was up 11% representing a margin of 5.7% versus a margin of 5.4% in the corresponding previous quarter.
- India hospital business revenues were at Rs 878 Cr versus Rs 831 Cr in Q4FY15. Operating EBITDAC in the quarter stood at Rs 130 Cr, representing a margin of 14.8% versus 15.4% in the corresponding previous quarter and 14.3% in the trailing quarter.
- ARPOB (Average Revenue per Occupied Bed) in the quarter stood at Rs 1.43 Cr as compared to Rs 1.32 Cr in Q4FY15, a growth of 8%. ALOS (Average length of stay) was at 3.59 days versus 3.66 days in the previous corresponding quarter, while Occupancy stood at 71% versus 72% in Q4 FY15.

- The India diagnostics business recorded net revenues of Rs 192 Cr compared to Rs 185 Cr in Q4FY15. The operating EBITDA was at Rs 44 Cr, representing an improved EBITDA margin of 22.8% compared to 21.6% in Q4FY15.

Reported Group Financial Highlights for FY16 and Q4FY16

The reported results for FY16 and Q4 FY16 are not comparable with the corresponding previous period due to progressive divestments of the Company's international businesses.

- Consolidated Group Revenues for FY16 were at Rs 4,276 Cr versus Rs 4,140 Cr for the previous year. Consolidated PAT after Minority Interest and share in associates (PATMI) for FY16 was at Rs (24.9) Cr versus Rs (143.7) Cr in FY15. The PATMI for the year includes a net exceptional loss of Rs 33.2 Cr.
- Consolidated Group Revenues for Q4FY16 were at Rs 1,088 Cr versus Rs 1,064 Cr for the corresponding previous quarter. Consolidated PAT after Minority Interest and share in associates (PATMI) for Q4FY16 was at Rs (91) Cr against Rs (17.5) Cr in Q4FY15. The PATMI for the quarter includes an exceptional loss of Rs 64.2 Cr.

Commenting on the results, Mr Bhavdeep Singh, CEO, Fortis Healthcare Ltd, said, "Our focus during the year has been on delivering clinical excellence and superior patient care. Our people work ceaselessly every single day at all our hospitals to make sure that our patients continue to receive the best. We have made substantial headway, in both these critical areas. I am confident that we are moving in the right direction and will continue to record gains as we go forward." Other Business Highlights – FY16.

- In line with its stated strategy to focus on India, the Company in Q1 of FY 2016 completed the last of its international divestments i.e. RadLink and Fortis Surgical Hospital in Singapore for a sale consideration of SGD 166 Mn in total.
- The Company in Q1FY16 successfully redeemed USD 100 Mn Foreign Currency Convertible Bonds (FCCBs) issued in 2010. The redemption was made from the Company's existing cash proceeds.
- In Q2FY16, the Company increased its equity stake in SRL Limited taking its current stake to 56%. It acquired a 3.1% stake from Sabre Partners Trust, Spring Healthcare (P) Limited and Spring Healthcare India Trust.
- In Septemebr 2015, the Company launched La Femme, Bengaluru, a 70 bed comprehensive and distinctive boutique hospital for women offering a holistic range of medical services.
- During Q3FY16, the Company acquired a 100% equity stake in Religare Health Trust Trustee Manager Pte Ltd, [a company incorporated in Singapore that acts as Trustee Manager to Religare Health Trust (RHT), of which the Company is Sponsor].

- In February 2016, the Company's Board approved the acquisition of a 51% economic interest in Fortis Hospotel Limited (FHTL), a subsidiary of the Religare Health Trust (RHT). As a result of the majority acquisition of FHTL, it will become a subsidiary of Fortis and hence be consolidated with Fortis. The transaction would result in a lower service fees i.e. net business trust fees that Fortis pays to the RHT thereby benefitting its operating profitability (EBITDA). For FY16, the net business trust fees paid for these two clinical establishments was approx. Rs 196 Cr. The transaction which is awaiting the required regulatory and statutory approvals is expected to be completed soon.
- The Company continued to maintain a healthy Balance Sheet with a net debt to equity ratio of 0.16x as on 31st March 2016 (0.24x times as on 31st March 2015). Net debt was at Rs 753 Cr (including FCCBs of Rs 562 Cr). Excluding the said FCCBs which are significantly in the money (conversion at Rs 99 per share), the net debt of the Company was at a low Rs 190 Cr representing a net debt to equity of 0.04x times.

NEW GROWTH INITIATIVES

- Continuing with its asset light growth strategy, Fortis has embarked on a well- defined plan through the "O&M" model to capitalise on the opportunities available in select geographies with negligible healthcare infrastructure and a burgeoning population requiring affordable good quality healthcare services. The Company (Fortis) is working actively to enter into collaborations with third parties for entering into operations and management contracts. Fortis under its brand, will lend its expertise in the field of hospital operations along with its systems and processes for a management fee. It will also supplement this by providing project consultancy services and technical inputs during the planning and implementation phase. While a number of such options are currently under evaluation, the Company has as on date signed definitive agreements each in Rajasthan, Assam, Bangladesh and Congo (Africa).

Key Highlights FY 16 - Hospital Business

- In FY16, the top 10 facilities contributed approx. 76% of the hospital business revenue. Most facilities, including the larger ones at FMRI, BG Road, Mulund, Noida, Anandpur, Vashi, CH Road and Ludhiana continued to exhibit growth momentum both in terms of revenues and operating margins.
- The contribution of International sales to the overall revenue of the Hospital business stood at 10 % (Rs 342 Cr), a growth of 8% over the the previous year. The Company with its high quality infrastructure and world class clinical talent, has further strengthened its focus on international sales and expects to see a strong uptick from this segment going forward.
- The Company's transplant program has been encouraging and has picked up in the year gone by. Revenue from transplant procedures grew by 36%. There was also a 2x increase in the number

of heart transplant procedures performed at Fortis. Healthy growth was also visible in Liver and kidney transplant procedures. This further signifies that the Company is making headway in moving towards complex, high end tertiary and quaternary care treatments.

- The Company introduced and expanded its clinical programs and service offerings in several facilities in its network. These included :
 - The setting up of a fully integrated Center of Excellence for Liver and Digestive diseases, at the Fortis Escorts Heart Institute (FEHI), Delhi.
 - The Da Vinci XI System, was commissioned at FMRI. This is an advanced robotic surgical technology for performing minimally invasive surgery. It allows surgeons to operate with pin point accuracy and is patient friendly as it provides a number of benefits that include reduced blood loss, fewer complications and a shorter hospital stay.
 - The Company, in line with its core value of patient centricity became the first private healthcare chain in India to monitor clinical outcomes starting with different cardiac procedures undertaken at the Fortis Escorts Heart Institute (FEHI). The plan is to gradually expand coverage to other key specialties.

Key Highlights FY 16 - Diagnostics Business

- The lab medicine i.e. the pathology business contributed 88% to total revenues and grew 14% over the previous year. The contribution of the imaging business to total revenues declined to 8% from 13% in the corresponding previous period, mainly due to network rationalization. Clinical Trials, Wellness and the International segment contributed 4% to the overall revenues of the Diagnostics business.
- SRL performed over 14.5 million accessions during the year, a 6% growth over last year. Through these accessions it undertook 32.7 million tests, up 8% as compared to 30.4 million tests in FY 15.
- SRL continued to grow its laboratory and collection centre network; adding 66 new laboratories and 141 collection centers while rationalising its portfolio with the closure of 15 laboratories and 388 collection centers.
- As of March 31, 2016, SRL had a network of 314 labs and approx. 7,200 collection points. (FY15 264 labs and 6400 collection points)

Awards & Accolades - Q4FY16

- Mr Malvinder Mohan Singh, Executive Chairman, Fortis Healthcare, was honoured with the 'Entrepreneur of the Year' award at the Asia Pacific Entrepreneurship Awards (APEA) 2016.
- Two Fortis facilities – Fortis Noida and Fortis Mohali – won the first and second prizes respectively in the Hospitals Sector (with more than 10 lakh kwh/year consumption category).

- Fortis Hospital, Noida, and Fortis Hospital, Anandapur, were recognised as Centres of Excellence in Emergency Medicine by the Society for Emergency Medicine, India.
- The Nursing Teams at Fortis Hospital, Mulund, and Fortis Hospital, Bannerghatta Road, Bengaluru, won the coveted Association of Healthcare Providers of India (AHPI) Award for Nursing Excellence.
- Dr Ashok Seth, Chairman, Fortis Escorts Heart Institute, New Delhi, became the first Indian doctor to be invited by the US Food & Drug Administration's (FDA) Medical Panel in Washington to present his experience regarding the use of Bioabsorbable Stents.
- Fortis Hiranandani, Vashi, won two Quality Excellence awards for 'Best Healthcare Services' and 'Dedicated Service' at the 5th CMO Asia World Quality Congress, held in Mumbai.
- Dr Priyadarshi Ranjan, Kidney Transplant Surgeon, Fortis Hospital, Mohali, was recognised by the Limca Book of Records 2015 for performing a successful kidney transplant on the heaviest patient so far in India, weighing 160 kgs.

Some Cases of Clinical Excellence at Fortis - (Q4)

- Fortis Centre for Heart Failure & Transplant at Fortis Malar, Chennai, under the astute leadership of Dr K. R. Balakrishnan, Director, Cardiac Sciences and Dr Suresh Rao K. G., Head Cardiac Anaesthesia and Critical Care, created history by crossing the 75th successful heart transplant milestone. The hospital also created a record by performing two heart transplants in a span of 7 hours.
- The Bone Marrow Transplant Team at Fortis Memorial Research Institute (FMRI), Gurgaon, conducted its 100th Bone Marrow Transplant in less than three years of becoming operational. This puts FMRI amongst the top few centres across India to have crossed the 100-BMT mark.
- A team of doctors led by Dr K. S. Iyer, Executive Director, Paediatric & Congenital Heart Diseases, FEHI, performed a complex 7-hour long open heart surgery on a month-old baby from Nairobi, Kenya, suffering from three major cardiac ailments — Transposition of Great Arteries (TGA), Ventricular Septal Defect (VSD) and Patent Ductus Arteriosus (PDA).
- A 44-day-old child from Bhilwara, Rajasthan, became India's youngest patient to be revived after a successful surgery for Tetralogy of Fallot (TOF), a complex congenital heart disease, at Fortis Escorts Hospital, Jaipur. The Primary Single Stage Corrective surgery was conducted by a team led by Dr Sunil Kaushal, Director and Chief Paediatric Cardiac Surgeon.
- A 30-year-old patient from Jamshedpur suffering from Hemangioblastoma, a rare benign tumour that occurs in blood vessels of the brain and spinal cord, was successfully operated upon by a team of doctors led by Dr Amitabha Chanda, Consultant Neurosurgeon, Fortis Hospital, Anandapur.
- An 8-year old girl from Oman suffering from Cerebral Palsy and severe spasticity was successfully treated by a team led by Dr Rahul Gupta, Senior Consultant, Neurosurgery, Fortis Noida.

- A 21-year old patient from Saudi Arabia was cured of a congenital abnormal curvature of spine (Kyphoscoliotic Deformity) after a 12-hour long operation, conducted by a team led by Dr Ashwani Maichand, Head, Minimal Access Orthopaedic Surgery, at Fortis Hospital, Shalimar Bagh, New Delhi.
- 3D printing was used by a team led by Dr Vijay Agarwal, Chief of Paediatric Surgery, and Dr Swati Garekar, Paediatric Cardiologist, Fortis Hospital, Mulund, to meticulously plan a rare surgery, the Nikaidoh Operation. Very few centres around the world are capable of performing the operation.
- A combined team of highly skilled surgeons from the Urology, Cardio-thoracic Surgery and Anaesthesiology departments at Fortis Hospital, Bannerghatta Road, Bengaluru, successfully treated a 65-year old patient of Renal Cell Carcinoma, a type of Kidney Cancer. The team, led by Dr Mohan Keshavamurthy, Director - Urology, Uro-oncology, Andrology & Transplantation Surgery, and Dr Murali Manohar V, Consultant Cardiovascular Thoracic Surgeon, was able to remove the malignant tumour completely after a complex and specialised operation.



About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka with 54 healthcare facilities (including projects under development), approximately 10,000 potential beds and 314 diagnostic centres.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

For further details please contact:

Raghu Kochar
Fortis Healthcare Ltd
9811617256

Anurag Kalra / Gaurav Chugh
Fortis Healthcare Ltd
9810109253 / 9958588900